C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Dexamethasone and tocilizumab have been associated with reduction in mortality, however, the beneficial effect is not for all patients and the impact on viral replication is not well defined. We hypostatized that C-reactive protein (CRP) could help in the identification of patients requiring anti-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Camon, Ana M., Alonso, Rodrigo, Muñoz, Francisco J., Cardozo, Celia, Bernal-Maurandi, Javier, Albiach, Laia, Agüero, Daiana, Marcos, M. Angeles, Ambrosioni, Juan, Bodro, Marta, Chumbita, Mariana, De la Mora, Lorena, Garcia-Pouton, Nicole, Dueñas, Gerard, Hernandez-Meneses, Marta, Inciarte, Alexy, Cuesta, Genoveva, Meira, Fernanda, Morata, Laura, Puerta-Alcalde, Pedro, Rico, Verónica, Herrera, Sabina, Tuset, Montse, Castro, Pedro, Prieto-González, Sergio, Almuedo, Alex, Muñoz, José, Mensa, Josep, Sanjuan, Gemma, Nicolas, J. M., Del Rio, Ana, Vila, Jordi, García, Felipe, Martínez, José Antonio, Garcia-Vidal, Carolina, Soriano, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960074/
https://www.ncbi.nlm.nih.gov/pubmed/35347166
http://dx.doi.org/10.1038/s41598-022-08882-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960074/
https://www.ncbi.nlm.nih.gov/pubmed/35347166
http://dx.doi.org/10.1038/s41598-022-08882-x

Ejemplares similares